The Pharma Data

AUGUST 19, 2021

today announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now under evaluation with the European Medicines Agency (EMA). In June 2021, Gilead submitted a New Drug Application (NDA) for lenacapavir seeking U.S.

Medicine 52

Medicine Marketing Drugs FDA Approval 52

The Pharma Data

MARCH 22, 2021

p<0.0001). p<0.0001). p<0.0001). All tested doses met the primary endpoint, rapidly and significantly reducing patients’ viral load (log10 copies/mL) compared to placebo (p<0.001), with all doses demonstrating similar efficacy. 1 COVID-19-related hospitalization or death through day 29. Risk reduction.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 7, 2023

Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer Gilead Sciences, Inc. 0.95]; nominal p=0.0133). The European Medicines Agency has also validated a Type II Variation Marketing Authorization Application for Trodelvy in HR+/HER2- metastatic breast cancer.

HR 40

HR Medicine Clinical Development Marketing 40

The Pharma Data

JUNE 30, 2021

–(BUSINESS WIRE)– Gilead Sciences, Inc. Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the U.S. Key data on lenacapavir will be presented during the 11th International AIDS Society (IAS) Conference on HIV Science in July 2021. FOSTER CITY, Calif.–(BUSINESS

Drugs 52

Drugs Trials RNA Development 52

The Pharma Data

JUNE 30, 2021

With a median follow-up of two years, the study met the primary endpoint of event-free survival (EFS; hazard ratio 0.398, p <0.0001). Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with commercial manufacturing operations in North America and Europe. About Gilead Sciences.

Vaccination 52

Vaccination Vaccine Trials Medicine 52

The Pharma Data

APRIL 7, 2021

–(BUSINESS WIRE)– Gilead Sciences, Inc. 0.54; p<0.0001). 0.62; p<0.0001), representing a 49% reduction in the risk of death. The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. FOSTER CITY, Calif.–(BUSINESS

HR 52

HR Genotype FDA Approval Genotoxicity 52

XTalks

SEPTEMBER 14, 2020

For example, the S&P 500 is just 100 points below its pre-pandemic peak while NASDAQ had fully recovered its losses by early June and is now reporting record highs. Meanwhile, Gilead Sciences, who is behind remdesivir, has declared that it will charge $3,120 to treat a single patient, at least those with private insurance in the US.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92